HeraMED (ASX:HMD), a medtech firm specializing in maternity care, has seen a 36% surge in its share price following the initiation of a clinical trial at Gold Coast Hospital. This internationally recognized institution manages over 5000 pregnancies annually and is currently undergoing a digital transformation under its Digital 2024 strategic plan.
The trial, expected to span six to nine months, will assess the impact of HeraMED's HeraCARE and HeraBEAT platforms on up to 90 pregnancies. HeraCARE is a remote patient monitoring program for pregnancy and post-partum care, while HeraBEAT is a medical-grade fetal heart rate monitor. The evaluation will focus on clinical usability, patient satisfaction, and economic considerations.
Ahead of the trial launch, HeraMED completed necessary platform configuration, customization, workflow integration, and set-up. Following this meticulous platform completion, the company went live. In management changes related to the trial, David Groberman stepped down as HeraMED's CEO and managing director but continues as a non-executive product strategist. The search for his successor is ongoing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.